Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold

References

• Nieschlag E. Late-onset hypogonadism: a concept comes of age. Andrology. 2020;8(6):1506–1511. doi:10.1111/andr.12719.
   PubMed Web of Science ®Google Scholar
• Kaufman JM. Diagnosis of hypogonadism in ageing men. Rev Endocr Metab Disord. 2022;23(6):1139–1150. PMID: 36355322 doi:10.1007/s11154-022-09763-4.
   PubMed Web of Science ®Google Scholar
• Huhtaniemi IT, Wu FCW. Ageing male (part I): pathophysiology and diagnosis of functional hypogonadism. Best Pract Res Clin Endocrinol Metab. 2022;36(4):101622. doi:10.1016/j.beem.2022.101622.
   PubMed Web of Science ®Google Scholar
• Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the european male ageing study. J Clin Endocrinol Metab. 2010;95(4):1810–1818.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Hackett GI, Strange RC. Sex hormone binding globulin: a review of its interactions with testosterone and age, and its impact on mortality in men with type 2 diabetes. Sex Med Rev. 2019;7(4):669–678. doi:10.1016/j.sxmr.2019.06.006.
   PubMed Web of Science ®Google Scholar
• Marriott RJ, Murray K, Adams RJ, et al. Factors associated with circulating sex hormones in men: individual participant data meta-analyses. Ann Intern Med. 2023;176(9):1221–1234. doi:10.7326/M23-0342.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–3672. doi:10.1210/jcem.84.10.6079.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Almeida OP, Hyde Z, et al. Higher serum free testosterone is associated with better cognitive function in older men, while total testosterone is not. The health in men study. Clin Endocrinol (Oxf). 2008;68(3):404–412. doi:10.1111/j.1365-2265.2007.03055.x.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Marriott RJ, Antonio L, et al. Associations of serum testosterone and sex hormone-binding globulin with incident cardiovascular events in Middle-aged to older men. Ann Intern Med. 2022;175(2):159–170. doi:10.7326/M21-0551.
   PubMed Web of Science ®Google Scholar
• Ivell R, Heng K, Severn K, et al. The biomarker INSL3 as a predictor of age-related morbidity: findings from the EMAS cohort. Front Endocrinol. 2022b;13:1016107. doi:10.3389/fendo.2022.1016107.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Ng Tang Fui M, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrology. 2020;8(6):1519–1529. doi:10.1111/andr.12705.
   PubMed Web of Science ®Google Scholar
• Ivell R, Anand-Ivell R. The biology of insulin-like factor 3 (INSL3) in human reproduction. Hum Reprod Update. 2009;15(4):463–476. doi:10.1093/humupd/dmp011.
   PubMed Web of Science ®Google Scholar
• Albrethsen J, Juul A, Andersson AM. Mass spectrometry supports that the structure of circulating human insulin-like factor 3 is a heterodimer. Front Endocrinol (Lausanne). 2020a;11:552. doi:10.3389/fendo.2020.00552.
   PubMed Web of Science ®Google Scholar
• Bay K, Hartung S, Ivell R, et al. Insl3 serum levels in 135 normal men and 82 men with testicular disorders: relation to semen quality and the LH-testosterone axis. J Clin Endocrinol Metab. 2005;90(6):3410–3418. doi:10.1210/jc.2004-2257.
   PubMed Web of Science ®Google Scholar
• Sadeghian H, Anand-Ivell R, Balvers M, et al. Constitutive regulation of the Insl3 gene in rat leydig cells. Mol Cell Endocrinol. 2005;241(1-2):10–20. doi:10.1016/j.mce.2005.03.017.
   PubMed Web of Science ®Google Scholar
• Anand-Ivell R, Heng K, Hafen B, et al. Dynamics of INSL3 peptide expression in the rodent testis. Biol Reprod. 2009;81(3):480–487. doi:10.1095/biolreprod.109.077552.
   PubMed Web of Science ®Google Scholar
• Foresta C, Bettella A, Vinanzi C, et al. A novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab. 2004;89(12):5952–5958. doi:10.1210/jc.2004-0575.
   PubMed Web of Science ®Google Scholar
• Johansen ML, Anand-Ivell R, Mouritsen A, et al. Serum levels of insulin-like factor 3, anti-Müllerian hormone, inhibin B and testosterone during pubertal transition in healthy boys: a longitudinal pilot study. Reproduction. 2014;147(4):529–535. doi:10.1530/REP-13-0435.
   PubMed Web of Science ®Google Scholar
• Albrethsen J, Johannsen TH, Jørgensen N, et al. Evaluation of serum insulin-like factor 3 quantification by LC-MS/MS as a biomarker of leydig cell function. J Clin Endocrinol Metab. 2020b;105(6):1868–1877. doi:10.1210/clinem/dgaa145.
   Web of Science ®Google Scholar
• Ivell R, Mamsen L, Andersen CY, et al. Role and expression of INSL3 in the fetal testis. Front Endocrinol. 2022a;13:868313. doi:10.3389/fendo.2022.868313.
   PubMed Web of Science ®Google Scholar
• Bay K, Virtanen HE, Hartung S, et al. The nordic cryptorchidism study group, toppari J. Insulin-like factor 3 levels in cord blood and serum from children: effects of age, postnatal hypothalamic-pituitary-gonadal axis activation, and cryptorchidism. J Clin Endocrinol Metab. 2007;92(10):4020–4027. doi:10.1210/jc.2007-0974.
   PubMed Web of Science ®Google Scholar
• Ivell R, Wade JD, Anand-Ivell R. Insulin-like factor 3 (INSL3) as a biomarker of leydig cell functional capacity. Biol Reprod. 2013;88(6):147–147. doi:10.1095/biolreprod.113.108969.
   PubMedGoogle Scholar
• Chong YH, Pankhurst MW, McLennan IS. The daily profiles of circulating AMH and INSL3 in men are distinct from the other testicular hormones, inhibin B and testosterone. PLoS One. 2015;10(7):e0133637. doi:10.1371/journal.pone.0133637.
   PubMed Web of Science ®Google Scholar
• Anand-Ivell R, Heng K, Severn K, et al. Association of age, hormonal, and lifestyle factors with the leydig cell biomarker INSL3 in aging men from the EMAS (european male aging study) cohort. Andrology. 2022;10(7):1328–1338. doi:10.1111/andr.13220.
   PubMed Web of Science ®Google Scholar
• Anand‐Ivell R, Wohlgemuth J, Haren MT, et al. Peripheral INSL3 concentrations decline with age in a large population of Australian men. Int J of Andrology. 2006;29(6):618–626. doi:10.1111/j.1365-2605.2006.00714.x.
   PubMedGoogle Scholar
• Anand-Ivell R, Tremellen K, Soyama H, et al. Male seminal parameters are not associated with leydig cell functional capacity in men. Andrology. 2021;9(4):1126–1136. doi:10.1111/andr.13001.
   PubMed Web of Science ®Google Scholar
• Eendebak RJAH, Swiecicka A, Gromski PS, et al. Ethnic differences in male reproductive hormones and relationships with adiposity and insulin resistance in older men. Clin Endocrinol (Oxf). 2017;86(5):660–668. doi:10.1111/cen.13305.
   PubMed Web of Science ®Google Scholar
• Albrethsen J, Frederiksen H, Andersson A-M, et al. Development and validation of a mass spectrometry-based assay for quantification of insulin-like factor 3 in human serum. Clin Chem Lab Med. 2018;56(11):1913–1920. doi:10.1515/cclm-2018-0171.
   PubMed Web of Science ®Google Scholar
• O'Connor, Daryl B., Corona, Giovanni, Forti, Gianni, et al. Assessment of sexual health in aging men in Europe: development and validation of the european male ageing study sexual function questionnaire. J Sex Med, 6(2008) 5: 1374–1385. doi:10.1111/j.1743-6109.2008.00781.x.
   PubMed Web of Science ®Google Scholar
• Ermetici F, Donadio F, Iorio L, et al. Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on leydig cell function. Eur J Endocrinol. 2009;161(6):853–859. doi:10.1530/EJE-09-0203.
   PubMed Web of Science ®Google Scholar
• Hirsch HJ, Eldar-Geva T, Gross-Tsur V, et al. Normal insulin-like peptide-3 levels despite low testosterone in adult males with Prader-Willi syndrome: variations in leydig cell function from infancy through adulthood. J Clin Endocrinol Metab. 2013;98(1):E135–143. doi:10.1210/jc.2012-2171.
   PubMed Web of Science ®Google Scholar
• Trabado S, Maione L, Bry-Gauillard H, et al. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients. J Clin Endocrinol Metab. 2014;99(2):E268–275. doi:10.1210/jc.2013-2288.
   PubMed Web of Science ®Google Scholar
• Pan Y, Jing J, Dong F, et al. Association between phthalate metabolites and biomarkers of reproductive function in 1066 chinese men of reproductive age. J Hazard Mater. 2015;300:729–736. doi:10.1016/j.jhazmat.2015.08.011.
   PubMed Web of Science ®Google Scholar
• Chang WH, Li SS, Wu MH, et al. Phthalates might interfere with testicular function by reducing testosterone and insulin-like factor 3 levels. Hum Reprod. 2015;30(11):2658–2670. doi:10.1093/humrep/dev225.
   PubMed Web of Science ®Google Scholar
• Chong YH, Pankhurst MW, McLennan IS. The testicular hormones AMH, InhB, INSL3, and testosterone can be independently deficient in older men. J Gerontol A Biol Sci Med Sci. 2017;72(4):548–553. doi:10.1093/gerona/glw143.
   PubMed Web of Science ®Google Scholar
• Chang WH, Wu MH, Pan HA, et al. Semen quality and insulin-like factor 3: associations with urinary and seminal levels of phthalate metabolites in adult males. Chemosphere. 2017;173:594–602. doi:10.1016/j.chemosphere.
   PubMed Web of Science ®Google Scholar
• Di Nisio A, De Toni L, Rocca MS, et al. Negative association between sclerostin and INSL3 in isolated human osteocytes and in klinefelter syndrome: new hints for testis-bone crosstalk. J Clin Endocrinol Metab. 2018;103(5):2033–2041. doi:10.1210/jc.2017-02762.
   PubMed Web of Science ®Google Scholar
• Luo K, Liu X, Nian M, Shanghai Birth Cohort., et al. Environmental exposure to per- and polyfluoroalkyl substances mixture and male reproductive hormones. Environ Int. 2021;152:106496. doi:10.1016/j.envint.2021.106496.
   PubMed Web of Science ®Google Scholar
• Ivell R, Anand-Ivell R. Insulin-like peptide 3 (INSL3) is a major regulator of female reproductive physiology. Hum Reprod Update. 2018;24(6):639–651. doi:10.1093/humupd/dmy029.
   PubMed Web of Science ®Google Scholar
• Anand-Ivell R, Tremellen K, Dai Y, et al. Circulating insulin-like factor 3 (INSL3) in healthy and infertile women. Hum Reprod. 2013;28(11):3093–3102. doi:10.1093/humrep/det349.
   PubMed Web of Science ®Google Scholar
• Yeom E, Shin H, Yoo W, et al. Tumour-derived Dilp8/INSL3 induces cancer anorexia by regulating feeding neuropeptides via Lgr3/8 in the brain. Nat Cell Biol. 2021;23(2):172–183. doi:10.1038/s41556-020-00628-z.
   PubMed Web of Science ®Google Scholar
• Rohayem J, Nieschlag E, Kliesch S, et al. Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation between constitutional delay of growth and puberty and hypogonadotropic hypogonadism. Andrology. 2015;3(5):882–887. doi:10.1111/andr.12088.
   PubMed Web of Science ®Google Scholar
• Abbara A, Koysombat K, Phylactou M, et al. Insulin-like peptide 3 and inhibin B as markers of testicular leydig and sertoli cells in constitutional delay of growth and puberty (CDGP) and congenital hypogonadotrophic hypogonadism (CHH). Front Endocrinol. 2022;13:1076984. doi:10.3389/fendo.2022.1076984.
   PubMedGoogle Scholar
• Santi D, Ivell R, Anand-Ivell R, et al. Effects of acute hCG stimulation on serum INSL3 and 25-OH vitamin D in klinefelter syndrome. Andrology. 2020;8(6):1720–1727. doi:10.1111/andr.12851.
   PubMed Web of Science ®Google Scholar
• Bay K, Matthiesson KL, McLachlan RI, et al. The effects of gonadotropin suppression and selective replacement on insulin-like factor 3 secretion in normal adult men. J Clin Endocrinol Metab. 2006;91(3):1108–1111. doi:10.1210/jc.2005-1865.
   PubMed Web of Science ®Google Scholar
• Rasmussen JJ, Albrethsen J, Frandsen MN, et al. Serum insulin-like factor 3 levels are reduced in former androgen users, suggesting impaired leydig cell capacity. J Clin Endocrinol Metab. 2021;106(7):e2664–e2672. doi:10.1210/clinem/dgab129.
   PubMed Web of Science ®Google Scholar
• Wittert G, Piantadosi C, McAinch A, et al. Effects of rapid, diet-induced weight loss on sexual function and lower urinary tract symptoms in obese men. Int J Obesity. 2007;31: s 119.
   Web of Science ®Google Scholar
• Ferlin A, Selice R, Carraro U, et al. Testicular function and bone metabolism–beyond testosterone. Nat Rev Endocrinol. 2013;9(9):548–554. doi:10.1038/nrendo.2013.135.
   PubMed Web of Science ®Google Scholar
• Facondo P, Delbarba A, Maffezzoni F, et al. INSL3: a marker of leydig cell function and Testis-Bone-Skeletal muscle network. Protein Pept Lett. 2020;27(12):1246–1252. doi:10.2174/0929866527666200925105739.
   PubMed Web of Science ®Google Scholar
• Ivell R, Alhujaili W, Kohsaka T, et al. Physiology and evolution of the INSL3/RXFP2 hormone/receptor system in higher vertebrates. Gen Comp Endocrinol. 2020;299:113583. doi:10.1016/j.ygcen.2020.113583.
   PubMed Web of Science ®Google Scholar